- Home
- PEPG
PEPG
PepGen Inc.
as 12-20-2024 4:00pm EST
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
| Founded: | 2018 | Country: | United States |
| Employees: | 76 | City: | BOSTON |
| Market Cap: | 118.3M | IPO Year: | 2022 |
| Target Price: | $14.67 | AVG Volume (30 days): | 297.7K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $19.30 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PepGen Inc. News
PEPG Breaking Stock News: Dive into PEPG Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating
MT Newswires
6 days ago
BofA Securities Downgrades PepGen to Underperform
MT Newswires
6 days ago
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
Business Wire
6 days ago
PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy
Business Wire
a month ago
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
Business Wire
a month ago
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Simply Wall St.
2 months ago
We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate
Business Wire
2 months ago
PepGen to Participate in Upcoming Investor Conferences
Compare PEPG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEPG PepGen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.